Impact__O on__O patients:__O An__B-PER increasing__O number__O of__O patients__O are__O waiting__O for__O a__O kidney__O transplant,__O and__O those__O with__O HLA__B-ORG antibodies__O are__O waiting__O disproportionately__O longer__O and__O have__O more__O health__O problems.__O
Our__O research__O on__O AIT__B-ORG has__O enabled__O the__O transplantation__O of__O more__O than__O 100__O of__O these__O immunologically__O (most__O patients__O have__O multiple__O HLA__B-ORG antibodies)__O and__O physiologically__O complex__O (patients__O may__O have__O cardiovascular__O insufficiency__O and__O rigidity)__O cases__O since__O 2008__O in__O Coventry__B-ORG alone.__O
Their__O complexity__O is__O illustrated__O by__O an__O average__O time__O of__O renal__O failure__O of__O 14__O years__O before__O we__O transplanted__O them;__O 71%__O had__O prior__O transplants,__O and__O 35%__O first__O developed__O renal__O failure__O as__O children.__O
The__O majority__O of__O these__O would__O probably__O not__O have__O received__O a__O transplant__O without__O the__O use__O of__O the__O new__O tools__O and__O techniques__O resulting__O from__O our__O research7,__O c,__O d,__O e.__O Shared__O knowledge__O from__O our__O research__O has__O resulted__O in__O the__O transplantation__O of__O over__O 350__O other__O similarly__O complex__O patients__O across__O the__O UK__B-LOC since__O 2008c,d,__O and__O f.__O The__O Associate__B-ORG Medical__O Director__O for__O Organ__B-PER Donation__I-PER at__O NHSBT__B-ORG has__O stated__O in__O supporting__O evidence,__O `The__O impact__O of__O their__O research__O has__O allowed__O greater__O access__O to__O transplantation__O for__O this__O group__O of__O patients__O who__O have__O hitherto__O been__O disadvantaged__O and__O the__O lessons__O learnt__O have__O been__O extrapolated__O into__O other__O areas__O of__O solid__O organ__O transplantation__O so__O leading__O to__O better__O outcomes__O in__O terms__O of__O quality__O and__O length__O of__O life...'c.__O
Impact__O on__O the__O community:__O A__O long__O wait__O for__O transplantation__O is__O not__O only__O a__O burden__O for__O the__O patient,__O but__O also__O impacts__O on__O relationships,__O family__O and__O work,__O resulting__O in__O emotional,__O social__O and__O financial__O sufferingg.__O
The__O benefits__O of__O successful__O transplantation__O of__O our__O patients__O are__O illustrated__O by__O media__O features__O (over__O 20__O TV,__B-ORG radio,__O and__O national__O media__O features,__O see__O source__O f__O for__O example).__O
Impact__O on__O health__O care__O professionals:__O The__O value__O of__O the__O research__O for__O the__O day-to-day__O clinical__O practice__O of__O the__O NHS__B-ORG is__O shown__O by__O the__O significant__O changes__O in__O clinical__O protocol,__O which__O we1-4,__O and__O others,__O have__O made__O since__O the__O 2003__O protocol.__O
This__O includes__O marked__O reductions__O in__O the__O intensity__O of__O immunosuppression__O in__O patients__O who__O do__O not__O develop__O rejection__O and__O this__O may__O account__O for__O the__O UHCW__B-ORG mortality__O rate__O being__O half__O that__O reported__O from__O the__O USA7,__B-MISC h.__O The__O research__O work,__O with__O the__O involvement__O of__O Higgins__B-ORG as__O chair__O of__O the__O guideline__O panel__O and__O Briggs,__B-ORG has__O led__O to__O the__O publication__O of__O national__O clinical__O guidelines__O for__O AIT__O by__O the__O British__B-ORG Transplantation__I-ORG Societyi.__I-ORG
These__O are__O the__O first__O such__O guidelines__O in__O the__O world__O and__O are__O important__O for__O the__O provision__O of__O standardised,__O high-quality__O care.__O
UK__B-ORG Commissioners__I-ORG expect__O transplant__O units__O to__O follow__O these__O guidelinesc.__O
As__O a__O result__O of__O our__O clinical__O research,__O UoW,__B-ORG NHSBT__I-ORG together__O with__O UHCW,__B-ORG have__O helped__O other__O transplantation__O units__O implement__O our__O AIT__B-ORG transplant__O protocol__O and__O business__O model__O for__O obtaining__O funding__O through__O the__O NHS,__B-ORG including__O DFPP__B-ORG and__O cryofiltrationi.__O
Specialist__O NHS__O Renal__O Centres__O that__O have__O benefited__O directly__O from__O our__O research__O in__O this__O way__O include__O Guy's,__B-ORG St__I-ORG Georges,__I-ORG Oxford,__O Cambridge,__O Cardiff,__B-PER Bristol,__I-PER Leeds,__I-PER Manchester,__I-PER Dublin__I-PER and__O Portsmouthd.__B-LOC
Two__B-MISC international__O clinical__O workshops__O in__O AIT__O at__O Warwick__O for__O the__O dissemination__O of__O knowledge__O to__O the__O patient__O benefit__O in__O 2008__O (80__O participants)__O and__O 2012__O (100__O participants)__O j,__O together__O with__O presentations__O at__O international__O meetingsh,__O and__O citations__O in__O the__O top__O clinical__O journali__O further__O illustrate__O the__O international__O impact__O of__O our__O work.__O
Our__O research__O has__O been__O instrumental__O in__O the__O generation__O of__O a__O national__O Registry__O for__O AIT__O in__O 2008__O as__O a__O research__O and__O audit__O tool.__O
This__O Registry__O was__O proposed__O and__O initiated__O by__O Higgins,__B-PER who__O presented__O the__O data__O nationally__O and__O internationally.__O
Other__O units__O such__O as__O Bristol__B-LOC and__O Cambridge__B-LOC have__O used__O Registry__B-ORG data__O provided__O by__O Higgins__B-MISC when__O assessing__O and__O developing__O their__O clinical__O programmes.__O
Impact__O on__O NHS:__B-ORG The__O financial__O impact__O of__O our__O programme__O locally__O has__O been__O highlighted__O by__O the__O Chief__O Executive__O of__O the__O University__B-ORG Hospital__I-ORG Coventry,__I-ORG who__O stated__O `the__O UHCW__B-ORG has__O received__O over__O &#163;6__O million__O income__O for__O these__O transplants,__O and__O savings__O to__O the__O NHS__B-MISC from__O these__O transplants__O exceeds__O &#163;5__O million__O over__O and__O above__O the__O extra__O costs__O of__O the__O programme'__O e.__O In__O addition,__O this__O cost__O benefit__O goes__O up__O by__O around__O &#163;1__O million__O a__O year__O as__O grafts__O continue__O to__O function__O and__O patients__O do__O not__O need__O dialysisk.__O
The__O impact__O is__O also__O reflected__O in__O the__O support__O from__O the__O National__B-ORG Director__I-ORG for__I-ORG Kidney__I-ORG Care__I-ORG at__O the__O UK__B-ORG Department__I-ORG of__I-ORG Health__I-ORG who__O stated__O that,__O `This__O research__O has__O enabled__O not__O only__O the__O transplant__O unit__O at__O UHCW__B-ORG to__O be__O extremely__O productive,__O but__O has__O facilitated__O the__O development__O of__O Antibody__B-ORG Incompatible__I-ORG Transplantation__I-ORG nationally.__O
The__O unit__O led__O the__O first__O NHS__B-MISC commissioned__O service__O for__O these__O transplants;__O national__O guidelines__O produced__O by__O the__O British__B-ORG Transplantation__I-ORG Society,__I-ORG and__O proposed__O the__O National__B-ORG Registry__I-ORG of__O cases__O that__O is__O run__O by__O NHS__B-ORG Blood__I-ORG and__O Transplant__B-LOC 'd.__O
Commercial__O impact__O and__O new__O innovation:__O The__O hardware__O for__O these__O techniques__O is__O provided__O through__O L.IN.C.__B-ORG
Medical__B-ORG Systems__I-ORG Ltd,__I-ORG whose__O Managing__B-ORG Director__I-ORG has__O stated__O that__O `...DFPP__O has__O become__O established__O as__O the__O treatment__O of__O choice__O for__O such__O patients__O in__O many__O transplant__O centres.__O
[Professor__B-ORG Higgins]__I-ORG was__O also__O the__O first__O physician__O to__O perform__O cryofiltration__O DFPP__B-ORG outside__O of__O North__B-LOC America__I-LOC and__O Japan...__B-LOC L.IN.C.__I-LOC
Medical__O Systems__O is__O an__O independent__O UK__B-LOC company__O and__O is__O now__O one__O of__O the__O key__O suppliers__O of__O extra-corporeal__O therapies__O providing__O innovative__O technologies__O that__O bring__O cost__O effective__O solutions__O to__O the__O NHS...'a.__B-MISC
Despite__O the__O advantages__O of__O DFPP__B-ORG and__O cryofiltration__O over__O other__O therapies,__O they__O remain__O non-selective.__O
In__O a__O formal__O collaboration__O with__O Pure__B-PER Transplant__I-PER Solutions__I-PER and__O Pure__B-LOC Protein__I-LOC LLC,__I-LOC Oklahoma__I-LOC City,__I-LOC we__O have__O successfully__O tested__O a__O pre-clinical__O device__O to__O selectively__O remove__O antibodies__O against__O HLA__B-ORG on__O the__O donor__O kidney.__O
The__O Director__B-ORG of__I-ORG Pure__I-ORG Protein__I-ORG has__O stated__O in__O supporting__O evidence,__O `This__O is__O a__O well-developed__O collaboration__O between__O our__O biotechnology__O company...__O and__O the__O University__B-ORG of__I-ORG Warwick__I-ORG and__I-ORG University__I-ORG Hospital__I-ORG Coventry...__I-ORG with__O their__O academic__O and__O clinical__O credentials__O in__O AIT.__B-LOC
Much__O progress__O has__O been__O made__O and__O ...__O discussions__O with__O investors__O have__O started__O to__O take__O this__O device__O into__O clinical__O patient__O testing'__O b.__O Additionally,__B-ORG we__O are__O collaborating__O on__O the__O development__O of__O a__O novel__O assay__O to__O measure__O HLA__B-ORG antibody__O potency,__O with__O a__O first__O use__O preproduction__O product__O and__O data__O presented__O at__O the__O 2013__O American__B-ORG Society__I-ORG of__I-ORG Histocompatibility__I-ORG meeting.__O
